Company profile · federal money
Paramita Therapeutics Inc
Paramita Therapeutics Inc received $353.0K in federal awards in FY2025. Largest customer: Department of Health and Human Services ($353.0K).
- FY2025 federal obligations
- $353.0K
Largest customers: Department of Health and Human Services $353.0K
Data through 2026-09-30; source: USAspending.gov.
Gathering everything on record…
From public government records, which may contain errors. Check the official source before relying on a number. Not financial, legal or investment advice. Terms · About the data
SBIR & STTR awards
2 small-business research awards (0 Phase II) worth $609.0K, 2021–2025.
- Novel multivalent PSMA-targeted taxane-conjugates for bone metastases in prostate cancer Department of Health and Human Services · SBIR Phase I · $353.0K · 2025
- SBIR Phase I: Novel COVID-19 Dual-function Therapeutic/Vaccine Product National Science Foundation · SBIR Phase I · $256.0K · 2021
All of its SBIR & STTR awards · SBA's SBIR.gov data